

# Diabetes during Pregnancy: Impacts on Maternal and Fetal Health, Pathophysiology, Risk Factors, Management and Long-Term Outcomes

Sokolayam Ibrahim\*

Cardiology Department, University of Lagos, Nigeria

## Corresponding Author\*

Sokolayam Ibrahim

Cardiology Department, University of Lagos, Nigeria

E-mail: si.ibrahim@sokolayan.com

**Copyright:** © 2024 Ibrahim S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the v

**Received:** 01-Aug-2024, Manuscript No. jdm-24-33962; **Editor assigned:** 03-Aug-2024, PreQC No. jdm-24-33962; **Reviewed:** 17-Aug-2024, QC No. jdm-24-33962; **Revised:** 22-Aug-2024, Manuscript No. jdm-24-33962; **Published:** 29-Aug-2024, DOI: 10.35248/2155-6156.10001153

## Abstract

Diabetes during pregnancy, also known as gestational diabetes mellitus (GDM), is a significant public health concern affecting both maternal and fetal health. This comprehensive review examines the effects of diabetes during pregnancy, focusing on maternal and fetal outcomes, pathophysiology, risk factors, management strategies, and long-term consequences for both mother and child. Understanding the complexities of GDM is crucial for healthcare professionals to provide optimal care and improve outcomes for pregnant women with diabetes.

## Introduction

Diabetes during pregnancy can be broadly categorized into two types: pregestational diabetes mellitus (PGDM), which includes type 1 and type 2 diabetes existing before pregnancy, and gestational diabetes mellitus (GDM), which is diagnosed for the first time during pregnancy. Both types pose significant risks to maternal and fetal health. With the rising prevalence of obesity, sedentary lifestyles, and advanced maternal age, the incidence of diabetes during pregnancy has increased globally. Understanding the effects of diabetes during pregnancy is essential for healthcare providers to implement effective screening, management, and follow-up strategies [1].

## Pathophysiology of diabetes in pregnancy

Pregnancy induces physiological changes that affect glucose metabolism, characterized by increased insulin resistance and altered glucose production. In normal pregnancies, insulin resistance gradually increases to provide an adequate supply of glucose to the growing fetus. However, in women with diabetes, these adaptations may result in hyperglycemia. In PGDM, chronic hyperglycemia affects placental development and function, while in GDM, hormonal changes from the placenta lead to insulin resistance, causing glucose intolerance. Poor glycemic control during pregnancy is associated with a range of complications for both the mother and fetus.

## Maternal outcomes of diabetes during pregnancy

**Preeclampsia and hypertension:** Women with diabetes during pregnancy are at an increased risk of developing hypertensive disorders, including preeclampsia. Chronic hyperglycemia contributes to endothelial dysfunction, oxidative stress, and inflammation, which are underlying factors in preeclampsia development. Studies indicate that the risk of preeclampsia is 2 to 4 times higher in women with GDM compared to non-diabetic pregnancies [2].

**Cesarean delivery:** Diabetes in pregnancy is associated with a higher likelihood of cesarean delivery due to complications such as fetal macrosomia (large-for-gestational-age baby), which increases the risk of obstructed labor. Cesarean delivery rates in women with GDM are approximately 45%, compared to 30% in the general obstetric population.

**Infections:** Pregnant women with diabetes have a higher risk of developing infections such as urinary tract infections (UTIs) and postpartum endometritis. Hyperglycemia impairs the immune response, increasing susceptibility to infections.

**Maternal morbidity and mortality:** Women with poorly controlled diabetes during pregnancy are at a greater risk of experiencing complications like diabetic ketoacidosis (DKA), hypoglycemia, and progression of diabetes-related complications such as retinopathy and nephropathy. These conditions contribute to increased maternal morbidity and mortality [3].

## Fetal and neonatal outcomes of diabetes during pregnancy

**Macrosomia and birth injuries:** One of the most common fetal complications of maternal diabetes is macrosomia, defined as a birth weight of more than 4,000 grams. Macrosomia increases the risk of birth injuries, such as shoulder dystocia, brachial plexus injury, and clavicle fractures, due to difficulties during delivery.

**Congenital anomalies:** Pregnancies complicated by pregestational diabetes are associated with a higher incidence of congenital anomalies, including cardiac defects, neural tube defects, and caudal regression syndrome. The risk of congenital anomalies is directly related to the degree of glycemic control during the first trimester when organogenesis occurs.

**Neonatal hypoglycemia:** Infants born to diabetic mothers are at risk of developing neonatal hypoglycemia due to the hyperinsulinemic state induced by chronic in utero hyperglycemia. After birth, the sudden cessation of maternal glucose supply, combined with high insulin levels, leads to hypoglycemia in the neonate [4].

**Respiratory distress syndrome (RDS):** Maternal hyperglycemia can delay fetal lung maturation, increasing the risk of respiratory distress syndrome in neonates. Even after adjusting for prematurity, infants of diabetic mothers have a higher likelihood of RDS compared to those of non-diabetic mothers.

**Perinatal mortality:** Poorly controlled diabetes in pregnancy is associated with a higher risk of stillbirth and neonatal death. Perinatal mortality rates are reported to be 4 to 5 times higher in pregnancies affected by diabetes compared to non-diabetic pregnancies.

## Long-term consequences for mother and child

**Maternal long-term risks:** Women who develop GDM have a significantly higher risk of developing type 2 diabetes later in life. Approximately 30-50% of women with GDM will develop type 2 diabetes within 10 years postpartum. Additionally, they are at an increased risk for cardiovascular diseases [5].

**Childhood obesity and metabolic disorders:** Offspring of mothers with diabetes during pregnancy are at increased risk for childhood obesity, glucose intolerance, and type 2 diabetes. Intrauterine exposure to hyperglycemia is hypothesized to cause epigenetic changes that predispose offspring to metabolic disorders.

## Management of diabetes during pregnancy

**Screening and diagnosis:** Early and accurate screening for GDM is crucial. The American Diabetes Association (ADA) recommends screening for undiagnosed type 2 diabetes at the first prenatal visit in women with risk factors. The "one-step" 75-gram oral glucose tolerance test (OGTT) at 24-28 weeks gestation is

commonly used for diagnosing GDM [6].

**Glycemic control:** The cornerstone of managing diabetes in pregnancy is maintaining optimal glycemic control to minimize maternal and fetal complications. The ADA recommends a target fasting blood glucose level of less than 95 mg/dL and a 1-hour postprandial level of less than 140 mg/dL.

**Diet and exercise:** Nutritional counseling and a balanced diet tailored to the individual's caloric and nutritional needs are fundamental. Regular physical activity, such as walking and moderate aerobic exercise, helps improve insulin sensitivity and glycemic control.

**Pharmacological therapy:** When lifestyle modifications are insufficient to achieve glycemic targets, insulin is the first-line treatment for GDM. Oral agents like metformin and glyburide may be considered, although insulin remains the preferred choice due to its safety profile [7,8].

**Monitoring and follow-up:** Regular fetal monitoring, including growth scans and non-stress tests, is essential to detect complications early. Postpartum follow-up is crucial to assess glucose tolerance and provide guidance on lifestyle modifications to reduce the risk of type 2 diabetes.

## Discussion

The review highlights that diabetes during pregnancy, including both gestational diabetes mellitus (GDM) and pregestational diabetes, significantly affects maternal and fetal health. Maternal outcomes include increased risks of preeclampsia, cesarean delivery, and infections. Fetal complications include macrosomia, congenital anomalies, neonatal hypoglycemia, and respiratory distress syndrome. Long-term risks involve the development of type 2 diabetes in mothers and childhood obesity and metabolic disorders in offspring. Effective management involves early screening, maintaining glycemic control through diet, exercise, and pharmacotherapy, and regular monitoring. A multidisciplinary approach is essential to reduce adverse outcomes. Improved understanding of GDM's pathophysiology and risk factors allows for better preventive measures and tailored treatments. Future research should focus on optimizing management strategies and exploring the genetic and epigenetic factors influencing GDM to improve both short- and long-term outcomes for mothers and their children [9,10].

## Conclusion

Diabetes during pregnancy, whether pregestational or gestational, presents significant challenges to maternal and fetal health. A multidisciplinary approach involving obstetricians, endocrinologists, dietitians, and pediatricians is essential for optimal management. Early diagnosis, tight

glycemic control, and comprehensive postpartum care can significantly reduce the risks associated with diabetes in pregnancy and improve long-term outcomes for both mother and child. Continued research and awareness are necessary to enhance the understanding and management of this complex condition, ultimately improving health outcomes for affected families.

## References

- Zhou R (2022) Investigating the Mechanisms of Pollen Typhae in the Treatment of Diabetic Retinopathy Based on Network Pharmacology and Molecular Docking. *Evid Based Complement Alternat M*.
- Rêgo S, Monteiro-Soares M, Dutra-Medeiros M, Soares F, Dias CC, et al. (2022) Implementation and Evaluation of a Mobile Retinal Image Acquisition System for Screening Diabetic Retinopathy: Study Protocol. *Diabetology* 3: 1-16.
- Klein R, Klein BF, Moss SE, Davis MD, DeMets DL, et al. (1989) The Wisconsin epidemiologic study of diabetic retinopathy: IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. *Arch Ophthalmol* 107: 237-243.
- Vujosevic S, Aldington SJ, Silva P (2020) Screening for diabetic retinopathy: new perspectives and challenges. *Lancet Diabetes Endocrinol* 8: 337-347.
- Ren Y (2022) Discovery of Therapeutic Candidates for Diabetic Retinopathy Based on Molecular Switch Analysis: Application of a Systematic Process. *Oxid Med Cell Longev*.
- Thomas RL, Halim S, Gurudas S, Sivaprasad S, Owens DR, et al. (2019) IDF Diabetes Atlas: a review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. *Diabetes Res Clin Pract* 157: 107840.
- AM Hendrick, MV Gibson, A Kulshreshtha (2015) Diabetic retinopathy. *Prim Care* 42: 451-464.
- Kollias AN, Ulbig MW (2010) Diabetic retinopathy: Early diagnosis and effective treatment. *Dtsch Arztebl Int* 107: 75-83.
- Duh EJ, Sun JK, Stitt AW (2017) Diabetic retinopathy: Current understanding, mechanisms, and treatment strategies. *JCI Insight* 2: 93751.
- Brown DM (2021) Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: Results from the panorama randomized clinical trial. *JAMA Ophthalmol* 139: 946-955.